Quantcast

Latest Pancreatin Stories

2011-08-29 12:20:01

Tokyo, Aug 29, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they will launch the pancreatic digestive enzyme replacement drug Lipacreon(R) Capsules 150 mg and Lipacreon(R) Granules 300mg Sachets (pancrelipase) on August 30 in Japan.Abbott Japan received approval to manufacture and market Lipacreon in Japan as a pancreatic digestive enzyme replacement in patients with pancreatic exocrine insufficiency (PEI) on April 22 of this year, with the drug...

2011-06-14 08:30:00

ABBOTT PARK, Ill., June 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON(R) (pancrelipase) Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). The CREON 3,000 units of lipase capsule provides the lowest dosage strength in the class approved by the FDA. This new option will enable more precise dosing titration in accordance with the...

2010-07-02 07:00:00

INDIANAPOLIS and CAMBRIDGE, Mass., July 2 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and Alnara Pharmaceuticals, Inc. today announced they have signed a definitive merger agreement whereby Lilly will acquire Alnara, a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases. Alnara's lead product in development is liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT). Liprotamase is under review by the...

2010-05-03 07:02:00

ABBOTT PARK, Ill.., May 3 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas...

2009-07-07 11:00:00

MARIETTA, Ga., July 7 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. today announced the commercial availability of CREON(R) (pancrelipase) Delayed-Release Capsules. Now available to be filled at pharmacies nationwide, CREON(R) was approved by the Food and Drug Administration (FDA) on April 30, 2009, for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) or other conditions. CREON(R) is the first and only pancreatic enzyme product (PEP) to receive FDA approval...

2009-05-07 10:30:44

The U.S. Food and Drug Administration announced approval Thursday of the drug Creon, a pancreatic enzyme replacement. The FDA said Creon (pancrelipase) is designed to help patients with cystic fibrosis and exocrine pancreatic insufficiency digest and absorb nutrients from foods. The federal agency said Creon is the first FDA-approved delayed-release pancreatic enzyme replacement product to be marketed in the United States as a result of the FDA's unapproved drugs initiative. Creon, which...

2008-10-30 12:00:21

US-based pharmaceutical company Digestive Care has completed the submission of the new drug application for Pancrecarb, used in the treatment of exocrine pancreatic insufficiency, to the FDA. The FDA has previously granted the product fast track designation and approved a rolling new drug application (NDA) submission schedule. The company has recently announced results of the completed randomized, double-blind, placebo-controlled, multi-center, crossover study on Pancrecarb. Tibor...

2008-01-16 03:00:12

By Hauenschild, Annette Ewald, Nils; Klauke, Thorsten; Liebchen, Ariane; Bretzel, Reinhard Georg; Kloer, Hans-Ulrich; Hardt, Philip Daniel ABSTRACT. Background: In some diseases, patients require high- calorie tube feeding with standard enteral formulas usually administered via temporal feeding tubes. One frequent pathophysiological condition in a relevant number of these patients is exocrine pancreatic insufficiency. Patients unable to swallow capsules might benefit from a liquid...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.